Table 2.
Results of primary and sensitivity analyses of eGFR at month 24
| Intervention, Mean (95% CI) | Control, Mean (95% CI) | Intervention Minus Control, Mean Diff (95% CI) | P Value | |
|---|---|---|---|---|
| ITT population | ||||
| eGFR (Filler and coworkers18) | 61.8 (45.3 to 78.2) | 60.1 (44.1 to 76.0) | 1.7 (−10.2 to 13.6) | 0.77 |
| eGFR (CKiD19) | 69.2 (53.1 to 85.3) | 68.8 (53.4 to 84.2) | 0.4 (−11.2 to 12.0) | 0.95 |
| Population A | ||||
| eGFR (Filler and coworkers18) | 62.7 (45.8 to 79.7) | 61.49 (44.8 to 78.1) | 1.2 (−11.2 to 13.6) | 0.84 |
| eGFR (CKiD19) | 70.0 (53.4 to 86.6) | 70.24 (54.2 to 86.3) | −0.2 (−12.3 to 11.8) | 0.97 |
| Population B | ||||
| eGFR (Filler and coworkers18) | 66.2 (50.7 to 81.7) | 60.8 (46.0 to 75.6) | 5.4 (−6.4 to 17.3) | 0.36 |
| eGFR (CKiD19) | 74.1 (59.2 to 89.0) | 69.1 (55.1 to 83.1) | 5.1 (−6.3 to 16.4) | 0.38 |
| Population C | ||||
| eGFR (Filler and coworkers18) | 61.9 (46.7 to 77.2) | 59.4 (44.5 to 74.2) | 2.6 (−8.4 to 13.6) | 0.64 |
| eGFR (CKiD19) | 69.6 (54.6 to 84.6) | 68.2 (53.9 to 82.6) | 1.4 (−9.4 to 12.2) | 0.80 |
Displayed are means and mean differences (Mean Diffs) with respective 95% CIs and P values from the analysis of covariance model including baseline eGFR, CMV prophylaxis, and study site.